


# THE ELEVENTH ANNUAL HCOP WINTER CONFERENCE

OJAI VALLEY INN AND SPA • OJAI, CALIFORNIA











## TABLE OF CONTENTS

Letter From The President	3
Objective Information	6
General Information	7
Program Information	8
Exhibitor Directory	11
Faculty Disclosures	13





Dear Colleagues,

## Welcome back to Ojai and the 11th Annual Winter Symposium of the Headache Cooperative of the Pacific (HCOP).

On behalf of the board of Directors and the Program Committee, I want to thank you for your continued support and participation. This year, we are celebrating our 11th year as an organization dedicated to supporting communication amongst research and headache providers, and promoting headache education in the western US. We have a very clinically directed program this year.

We would like to again honor the memory of Dr. Steven Graff-Radford. Steven was a founding Member of the Society, and our first president. His incisive thoughts, wit, and wonderful energy will be missed.

We will begin with a talk by Katharina Eikermann-Haerter on **changes in the brain in chronic migraine**, followed by a presentation from Dr. Robert Cowan on the **natural history of chronic migraine**. We will then have a discussion by Dr Susan Hutchinson and Dr Mollie Johnston on whether **chronic migraine should be viewed as primary or a secondary headache**, followed by question and answer, and a refreshment break.

That will be followed by discussion on the **best articles in headache** in 2017 by Dr Morris Levin and Thomas Ward. Following this there will be an **update on new therapeutics** by Dr Alan Rapoport. A presentation on **Sex, Pain and Death** by Jeffrey S. Mogil, will be followed by a question and answer break.

We will have a wine and cheese reception paired with the always popular **Wait, Wait Don't Tell Me** session with Dr. Levin. We will then have a welcome dinner, to which all are invited.

On Saturday Dr Brigitte Lovell will help us understand why "There is No Such Thing as "Atypical Facial Pain", and Dr Paul Grin will educate us on Temporomandibular Disorders and Headache. Then, Jes Olesen, MD & Thomas N. Ward, MD will then discuss Classification of Trigeminal Neuralgia.

After a question and answer break we will move into new migraine treatments. We will learn about **principles of antibody therapy** from Dr Morris Levin, and a review of **CGRP in migraine** by Dr. Andrew Charles, will be followed by discussion by Lawrence Newman of the topic "Are CGRP Antagonists Any Better than Treatments".

After Q&A and lunch, Dr Randal Weeks will discuss **Headache and the Contribution of Anxiety and Mood Disorders**, and Dr Larry Robbins will discuss **Treatment Strategies for the Refractory Chronic Migraine Patient**. This will be followed by Dr Weeks and Cowan discussing **Refractory Headache vs Refractory Patients**.

Following another Q&A break, Dr Brian McGeeney will present on **The Science Behind Psychedelics for Cluster Headache**, and I will interview one of my long-time cluster patients. To close this exciting conference, the **Steven Graff-Radford Lifetime Achievement Keynote Presentation "All You Need to Know About PACAP-38**" will be given by Dr Jes Olesen

The board is certain this will be another great meeting, bringing together world-class clinicians and researchers in headache medicine in a small, informal setting with lots of opportunity for interaction and questions.

Bert Vargas and Judy Lane have compiled a terrific agenda and we are grateful to them, as well as the volunteers, and especially Maripat Traino who has worked tirelessly throughout the year, to ensure that we have another very successful event.

You are what make this meeting great. Enjoy!

Sincerely,

Jack D. Schim, MD, FAHS President









#### ABOUT HCOP

The Headache Cooperative of the Pacific (HCOP) was formed in the summer of 2007 in response to a growing desire for better communication and education among healthcare providers who treat headache patients.

Modeled after the very successful Headache Cooperative of New England (HCNE) and under the guidance of its Founding President, Steven Graff-Radford, DDS (DECEASED) and Founding Director Alan Rapoport, MD, HCOP has been incorporated as a non-profit organization whose mission is to promote communication and spread headache information among headache caregivers and researchers, to provide headache education for non-headache specialists, and to increase understanding of headache in the community. Membership is open to all types of headache caregivers and we encourage our patients to form community support groups



#### **HCOP PROGRAM COMMITTEE**

#### **Program Co-Chair**

Judy Lane, MD
Medical Director, Colorado
Neurological Institute
Associate Professor of Family Medicine
and Pharmacy, University of Colorado
Denver, Colorado

#### **Program Co-Chair**

Bert Vargas, MD Director, Sports Neurology and Concussion Program, UT Southwestern Dallas, Texas

#### **Program Committee**

Robert Cowan MD Clinical Professor of Neurology, Stanford University Palo Alto, California

Alan Rapoport, MD Clinical Professor of Neurology, University of California Los Angeles Los Angeles, California



#### HCOP BOARD OF DIRECTORS

#### President

Jack Schim, MD
The Neurology Center of Southern California
Assistant Clinical Professor of Neuroscience,
University of California San Diego
San Diego, California

#### **Immediate Past President**

Robert Cowan MD Clinical Professor of Neurology, Stanford University Palo Alto, California

#### **Past President**

Steven Graff-Radford, DDS (DECEASED) Director of the Program for Headache and Orofacial Pain, Cedars-Sinai Los Angeles, California

#### **Vice President**

Susan Hutchinson, MD
Director and Founder, Orange County Migraine & Headache Center
Irvine, California

#### **Founding Chairman**

Alan Rapoport, MD Clinical Professor of Neurology, University of California Los Angeles Los Angeles, California

#### **Treasurer**

Ben Frishberg, MD Medical Director, The Neurology Center of Southern California San Diego, California

#### Secretary

Ken Moore, DDS HCOP Secretary Director, Cosmetic and Family Dentistry Roseville, California

#### Members-At-Large

Judy Lane, MD Medical Director, Colorado Neurological Institute Associate Professor of Family Medicine and Pharmacy, University of Colorado Denver, Colorado

Morris Levin, MD Director, UCSF Headache Center Professor of Neurology, University of California San Francisco San Francisco, California

Mollie Johnston, MD Assistant Professor, David Geffen School of Medicine at UCLA Los Angeles, CA

Abraham Jim Nagy, MD Medical Director, Nevada Headache Institute Assistant Clinical Professor of Neurology, University of Nevada School of Medicine Las Vegas, Nevada

Bert Vargas, MD
Director, Sports Neurology and Concussion
Program
UT Southwestern
Dallas, TexasRoseville, California

## HCOP MISSION STATEMENT

The mission of the Headache
Cooperative of the Pacific is to
promote communication and
spread headache information
among headache caregivers and
researchers, to provide headache
education for non-headache
specialists, and to increase
understanding of headache in the
healthcare community through:

- Advancing the science of headache through education and coordinated research
- Providing a forum to link providers of headache care throughout the western states
- Supporting access to appropriate care for our patients
- Increasing awareness about national and international organizations and journals devoted to headache research and patient care







#### CONFERENCE EDUCATIONAL OBJECTIVES

At the completion of this program, participants will be better able to:

- · Identify factors that will improve the care of women with chronic pain conditions including migraine.
- · More accurately identify patients with trigeminal neuralgia
- · Critically appraise the impact of newer migraine medications in the context of currently accepted treatment options

#### WHO SHOULD ATTEND

Attendance is open to healthcare professionals who treat or are interested the treatment of headache, specifically: Neurologists, General Practitioners, Internists, Headache Specialists, Psychologists, Psychiatrists, Dentists, Nurse Practitioners, Physician Assistants, Pharmacists.

#### **ACCREDITATION STATEMENT**

This activity is planned and implemented by the University of Minnesota, Interprofessional Continuing Education and the Headache Cooperative of the Pacific (HCOP). University of Minnesota, Interprofessional Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center

#### CREDIT DESIGNATION STATEMENTS

#### **American Medical Association (AMA)**

The University of Minnesota, Interprofessional Continuing Education designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits $^{\text{TM}}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **Other Healthcare Professionals**

Nurses, nurse practitioners, advanced practice nurses, pharmacists, and other health care professionals who participate in this CE activity may submit this statement of participation to their appropriate accrediting organizations or state boards for consideration of credit. The participant is responsible for determining whether this activity meets the requirements for acceptable continuing education.

#### DISCLOSURE STATEMENT

It is the policy of the University of Minnesota Office Of Continuing Professional Development to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All individuals (including spouse/partner) who have influence over activity content are required to disclose to the learners any financial relationships with a commercial interest related to the subject matter of this activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on, patients. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. Specific disclosure information for each presenter, activity director, and planning committee member will be shared with the learner prior to the presenter's presentation. Persons who fail to complete and sign this form in advance of the activity are not eligible to be involved in this activity.



### GENERAL INFORMATION

#### REGISTRATION

The registration desk will be located in the Hacienda Foyer and open the following hours:

Friday, January 26 8:00 AM – 5:00 PM Saturday, January 27 7:00 AM – 3:00 PM

#### EXHIBIT HALL

The HCOP Exhibit Hall is located in Hacienda Ballroom A and will be open during the following hours:

Friday, January 26 1:00 PM – 3:15 PM Saturday, January 27 7:00 AM – 3:00 PM

#### **ACKNOWLEDGEMENTS**

This activity is supported by educational funding donation provided by:

Allergan, Inc.

Amgen, Inc.

electroCore, LLC

**Eli Lilly and Company** 

**Supernus** 

**Teva Pharmaceuticals** 

The Headache Cooperative of the Pacific Gratefully Acknowledges the Support of our Conference Exhibit Hall from our Industry Supporters.

Allergan, Inc.

**AMGEN** 

**Avanir** 

**Cefaly Technology** 

**Cirrus Healthcare Products** 

electroCore, LLC

eNeura, Inc.

Impax Laboratories, Inc.

**Novartis** 

**Promius Pharma, LLC** 

Supernus Pharmaceuticals, Inc.

**Teva Pharmaceuticals Industry Ltd** 

**Upsher-Smith** 

Valeant Pharmaceuticals North America LLC

## ELEVENTH ANNUAL CONFERENCE FACULTY

Andrew C. Charles, MD
David Geffen School of Medicine at UCLA
Los Angeles, CA

**Robert P. Cowan, MD** Stanford University Palo Alto, CA

**Ben Frishberg, MD**The Neurology Center of Southern California
San Diego, CA

Paul Grin, DDS, MPH UCLA Orofacial Pain Los Angeles, CA

**Susan Hutchinson, MD**Orange County Migraine & Headache Center Irvine, CA

Mollie Johnston, MD UCLA Medical Center Los Angeles, CA

Katharina Eikermann-Haerter, MD Massachusetts General Hospital Boston, MA

**Judy Lane, MD** Blue Sky Neurology Denver, CO

Morris Levin, MD University of California, San Francisco San Francisco, CA

**Brigitte Lovell, DMD**Keeler Center for Headache & Orofacial Pain Ojai, CA

**Brian E. McGeeney, MD**Boston University School of Medicine Boston, MA

Jeffrey S. Mogil, PhD McGill University Montreal, CANADA

**Lawrence Newman, MD**NYU Langone Medical Center
New York, NY

Jes Olesen, MD University of Copenhagen Copenhagen, DENMARK

Alan Rapoport, MD University of California Los Angeles Los Angeles, CA

Larry Robbins, MD Robbins Headache Clinic Riverwoods, IL

Jack D. Schim, MD
The Neurology Center of Southern California
San Diego, CA

Bert Vargas, MD UT Southwestern Dallas, TX

**Thomas N. Ward, MD**Dartmouth Medical School Lebanon, NH

Randall Weeks, PhD
The New England Institute for Neurology
and Headache
Stamford, CT







## PROGRAM INFORMATION

#### FRIDAY, JANUARY 26

FRIDAY, JANUARY	7 26	
1:00 PM – 1:15 PM	Welcome Remarks Jack D. Schim, MD President, Headache Cooperative of the Pacific The Neurology Center of Southern California	
	Day 1 Introductory Remarks Judy Lane, MD & Co-chair, 2018 HCOP Winter Conference Blue Sky Neurology	Bert Vargas, MD Co-chair, 2018 HCOP Winter Conference UT Southwestern
1:15 PM – 1:45 PM	Chronic Migraine Changes the Brain Katharina Eikermann-Haerter, MD Massachusetts General Hospital	
1:45 PM – 2:15 PM	<i>Is Chronification the Natural History of Migraine</i> Robert P. Cowan, MD <i>Stanford University</i>	
2:15 PM – 2:45 PM	Primary Care and Neurology Perspectives: Is Chron Secondary Headache? Susan Hutchinson, MD & Orange County Migraine & Headache Center	ic Migraine Viewed as Either a Primary or A  Mollie Johnston, MD  UCLA Medical Center
2:45 PM – 3:00 PM	Q and A	
3:00 PM – 3:15 PM	Refreshment Break	
3:15 PM – 3:45 PM	Journal Club - Best Articles of 2017  Morris Levin, MD &  University of California, San Francisco	Thomas N. Ward, MD  Dartmouth Medical School
3:45 PM – 4:15 PM	<b>Therapeutic Update</b> Alan Rapoport, MD University of California Los Angeles	
4:15 PM – 4:45 PM	Sex, Pain and Death Jeffrey S. Mogil, PhD McGill University	

4:45 PM - 5:00 PM

Q and A



5:00 PM – 5:45 PM Wine and Cheese Reception

Wait, Wait, Don't Tell Me...

Facilitator: Morris Levin, MD

University of California, San Francisco

Panelist: Ben Frishberg, MD

The Neurology Center of Southern California

Judy Lane, MD

Blue Sky Neurology

Lawrence Newman, MD
NYU Langone Medical Center

Bert Vargas, MD *UT Southwestern* 

7:00 PM – 9:00 PM Welcome Dinner (ALL are invited)

### SATURDAY, JANUARY 27

7:00 AM – 7:45 AM	Continental Breakfast	
7:45 AM – 8:00 AM	Day 2 Opening Remarks  Judy Lane, MD & Bert Vargas, MD  Co-chair, 2018 HCOP Winter Conference Co-chair, 2018 HCOP Winter Conference Blue Sky Neurology UT Southwestern	nce
8:00 AM – 8:30 AM	There is No Such Thing as "Atypical Facial Pain" Brigitte Lovell, DMD Keeler Center for Headache & Orofacial Pain	
8:30 AM – 9:00 AM	<b>Headache Associated with Temporomandibular Disorders: a Clinical Update</b> Paul Grin, DDS, MPH UCLA Orofacial Pain	
9:00 AM – 9:40 AM	Classification of Trigeminal Neuralgia: Do Sensory Changes Occur?  Jes Olesen, MD & Thomas N. Ward, MD  University of Copenhagen Dartmouth Medical School	
9:40 AM – 9:55 AM	Q and A	
9:55 AM - 10:10 AM	Refreshment Break	
10:10 AM – 10:40 AM	Principles of Antibody Therapy Morris Levin, MD University of California, San Francisco	
10:40 AM – 11:10 AM	CGRP in Migraine Andrew C. Charles, MD David Geffen School of Medicine at UCLA	
11:10 AM – 11:50 AM	Are CGRP Antagonists Any Better than Current Evidence-Based Treatments? Lawrence Newman, MD NYU Langone Medical Center	
11:50 AM – 12:05 PM	Q and A	








12:05 PM – 1:00 PM	Lunch
1:00 PM – 1:30 PM	Headache and the Contribution of Anxiety and Mood Disorders Randall Weeks, PhD The New England Institute for Neurology and Headache
1:30 PM – 2:00 PM	Treatment Strategies for the Refractory Chronic Migraine Patient: What to Do When Your First Attempts Fail Larry Robbins, MD Robbins Headache Clinic
2:00 PM – 2:30 PM	Neurology and Psychiatry Perspectives: Are We Treating Refractory Headache or Refractory Patients? Robert P. Cowan, MD & Randall Weeks, PhD Stanford University The New England Institute for Neurology and Headache
2:30 PM – 2:45 PM	Q and A
2:45 PM – 3:00 PM	Refreshment Break
3:00 PM – 3:30 PM	The Science Behind Psychedelics for Cluster Headache Brian E. McGeeney, MD Boston University School of Medicine
3:30 PM – 3:40 PM	Interview with Cluster Patient Jack D. Schim, MD The Neurology Center of Southern California
3:40 PM – 3:55 PM	Q and A
3:55 PM – 4:40 PM	Steven Graff-Radford Lifetime Achievement Keynote Presentation  All You Need to Know About PACAP-38  Jes Olesen, MD  University of Copenhagen
4:40 PM – 4:55 PM	Q and A
4:55 PM – 5:05 PM	Closing Remarks Jack D. Schim, MD The Neurology Center of Southern California



### HCOP 2018 WINTER CONFERENCE EXHIBIT HALL







Booth #9



Booth #1

#### **EXHBITOR DIRECTORY**

Allergan, Inc.

2525 Dupont Drive Irvine, CA 92612

Phone: (714) 246-4500 Web: <u>www.allergan.com</u>

Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceutical, devices and biologic products for patients around the world.

For more information, visit Allergan's website at <a href="https://www.Allergan.com">www.Allergan.com</a>

AMGEN Booth #12

1 Amgen Center Drive/ 1 Health Plaza Thousand Oaks/ East Hanover

CA/NJ 91320/07936

Phone: 805-447-1000/862-778-8300

Web: <u>www.amgen.com/</u> <u>www.novartis.com</u>

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas.

**Avanir Pharmaceuticals** 

Booth #3

30 Enterprise, Suite 400 Aliso Viejo, CA 92656 Phone: (949) 389-6700

Email: <u>mediarelations@avanir.com</u>

Web: <u>www.avanir.com</u>

**CEFALY Technology** 

187 Danbury Road Wilton, CT 06897 USA Phone: (203) 309-5670 Email: info@cefaly.us

Web: <u>www.cefalytechnology.com</u>

www.cefaly.us

CEFALY Technology has developed unique medical devices for the acute and preventive treatments of migraine. The first Cefaly device received FDA approval in March 2014. The company's mission is to develop non-invasive, drug-free, neurological medical treatments. In addition to Cefaly devices for migraine treatments, the company is leading research on medical devices to treat coma, epilepsy and fibromyalgia.

**Cirrus Healthcare Products, LLC.** 

60 Main Street, PO Box 220 Cold Spring Harbor, NY 11724 USA

Phone: 631-692-7600

Email: grant@cirrushealthcare.com

Web: www.migrainex.net

MigraineX is an all-natural solution to weather-related migraines. With our patented CeramX filter, the middle ear undergoes a more gradual shift in pressure when weather changes. Use with your prescription or not! Plus, our free MigraineX app sends push notifications alerting of upcoming weather systems. So you're prepared.

electroCore, LLC

Booth #4

Booth #10

150 Allen Road, Suite 201 Basking Ridge, NJ 07920 Phone: (973) 290-0097

Email: summer.diaz@electroCoreLLC.com

Web: <u>www.gammaCore.com</u>

electroCore, LLC is a U.S.-based bioelectronic medicine healthcare company focused on developing its proprietary self-administered, non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, metabolic disorders and immunology. The initial target is the treatment of primary headaches (cluster headache and migraine) and the associated chronic co-morbidities.



eNeura, Inc.

Booth #14

715 N. Pastoria Ave Sunnyvale, CA 94085 Web: www.eneura.com

Prescribed by physicians but designed for patient use, the sTMS mini™ is the first portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go. The sTMS mini™ is indicated for the acute and prophylactic treatment of migraine.

Impax Laboratories, Inc.

Booth #7

31047 Genstar Road Hayward, CA 9454 Phone: 510.240.6080 Web: www.impaxlabs.com

Impax Specialty Pharma is a branded product division of Impax Laboratories®, Inc. Impax Specialty Pharma is focused on targeting significant unmet needs, with a primary focus on developing treatments for neurological disorders.

#### **AMGEN / Novartis Pharmaceuticals**

Booth #5

1 Amgen Center Drive/ 1 Health Plaza Thousand Oaks/ East Hanover CA/NJ 91320/ 07936

Phone: 805-447-1000/ 862-778-8300 Web: www.amgen.com/ www.novartis.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas.

#### **Promius Pharma, LLC**

Booth #2

107 College Road East Princeton, NJ 08540 USA Phone: 609-282-1400

Web: www.promiuspharma.com

Inspired by patients and driven by innovation, Promius Pharma is committed to bringing new products to market in dermatology and neurology that meet patients' needs and seamlessly fit into their everyday lives. For more information about how we are putting patients first, visit promiuspharma.com.

#### Supernus Pharmaceuticals, Inc.

Booth #11

1550 E Gude Drive
Rockvill, MD 20850 USA
Phone: 301.838.2500
Email: info@supernus.com
Web: www.supernus.com

We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

#### **Teva Pharmaceuticals**

Booth #8

1090 Horsham Road North Wales, PA 19454 Phone: 888-838-2872 Web: www.tevausa.com

At Teva, our goal is to transform the lives of those suffering from migraine and headache by creating solutions to reinvent the treatment paradigm and by placing people at the center of everything we do.

#### **Upsher-Smith Laboratories, LLC**

Booth #13

6701 Evenstad Dr. Maple Grove, MN 55369 Phone: 763-315-2000

Email: <u>uslinfo@upsher-smith.com</u>
Web: <u>www.upsher-smith.com</u>

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that has strived to deliver quality, affordable generic medications for nearly a century. In June 2017, Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that shares a similar philosophy of always putting patients first.

For more information, visit www.upsher-smith.com.

#### **Valeant Pharmaceuticals**

Booth #6

400 Somerset Corporate Boulevard Bridgewater, NJ 08807

Phone: (908) 927-1400

Email: Fernando.Arcila@valeant.com

Web: <u>www.valeant.com</u>

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company anchored by a collection of franchises with a common goal of improving people's lives. Valeant develops, manufactures and markets a broad range of branded & generic pharmaceuticals, OTC, and medical devices, marketed in more than 100 countries.

#### **DISCLOSURES**

Charles, Andrew: Dr. Andrew Charles is a consultant for Alder, Amgen, Inc., Biohaven, Eli Lilly and Company, and eNeura. He has received grant/research support from Takeda and honoraria for Amgen, Inc., Eli Lilly. Off Label Use: CGRP small molecule receptor antagonists and antibodies targeting CGRP or its receptor.

Cowan, Robert\*: Dr. Robert Cowan has nothing to disclose.

Dobrinina, Dasha\*: Ms. Dobrinina has nothing to disclose.

Eikermann-Haerter, Katharina: Dr. Katharina Eikermann-Haerter has nothing to disclose.

Frishberg, Benjamin: Dr. Benjamin Frishberg has nothing to disclose.

Grin, Paul: Dr. Paul Grin has nothing to disclose.

**Hutchinson, Susan:** Dr. Susan Hutchinson is a consultant for Allergan, Inc., Alder Bio, Amgen, Inc., Avanir, electroCore, Eli LIlly, Pernix Therapeutics, Supernus, and Teva Pharmaceuticals. She is also on the Speaker's Bureau for Allergan, Inc., Avanir, Pernix Therapeutics, and Supernus

Johnston, Mollie: Dr. Mollie Johnston has nothing to disclose.

Lane, Judy\*: Dr. Judy Lane has nothing to disclose.

Levin, Morris: Dr. Morris Levin has nothing to disclose.

Lovell, Brigitte: Dr. Brigitte Lovell is a consultant for Amgen, Inc. She is also on the Speaker's Bureau for Amgen, Inc., Avanir, and Pernix Therapeutics.

McGeeney, Brian: Dr. Brian McGeeney is a consultant for Alder Bio, Promius Pharma, LLC, and Pernix Therapeutics. He is also a stock shareholder in Pfizer, Inc.

Mogil, Jeffrey: Dr. Jeffrey Mogil has nothing to disclose.

**Newman, Lawrence**: Dr. Lawrence Newman is a consultant for Allergan, Inc., Amgen, Inc., Alder Bio, Eli Lilly and Company, Teva Pharmaceuticals and Supernus. He has also received honoraria; Allergan, Inc., Amgen, Inc., Alder Bio, Eli Lilly and Company, Teva Pharmaceuticals and Supernus.

Olesen Jes: Dr. Jes Olesen has nothing to disclose.

Rapoport, Alan: Dr. Alan Rapoport is a consultant for Acorda, Amgen, Inc., Avanir, Depomed, electroCore, LLC, Promius Pharma, LLC, Impax Laboratories, Eli Lilly and Company, Pernix Therapeutics, Teva Pharmaceuticals, and Zosano. He is also on the Speaker's Bureau for Avanir, Depomed, and Pernix Therapeutics. Off-Label Use: All experimental products I will speak on are unlabeled.

Riordan, Morgan\*: Ms. Riordan has nothing to disclose.

**Robbins, Lawrence:** Dr. Lawrence Robbins has nothing to disclose. Off-Label Use: Most of the treatments for refractory headache are off-label; there have been few RCTs for these approaches.

Schim, Jack: Dr. Jack Schim is a consultant for Allergan, Inc., Avanir, CoLucid, Eli Lilly and Company, Promius Pharma, LLC, Upshire-Smith, electroCore, and Pernix Therapeutics. He is also on the Speaker's Bureau for Allergan, Inc., Amgen, Inc., Acorda, Avanir, Depomed, Pernix Therapeutics, Promius Pharma, LLC, Teva Pharmaceuticals, Upshire-Smith. Dr. Schim has received grant/research support from Allergan, Inc., Amgen, Inc., and Teva Pharmaceuticals. He also has received honoraria from Allergan, Inc., Amgen, Inc., Acorda, Avanir, Depomed, Pernix Therapeutics, Promius Pharma, LLC, Teva Pharmaceuticals, and Upshire-Smith. Off-Label Use: onabotulinumtoxinA, verapamil, psilocybin for cluster.

**Traino, Maripat\***: Ms. Traino has nothing to disclose.

Vargas, Bert\*: Dr. Bert Vargas is a consultant for Amgen, Inc., Allergan, Inc., Alder, Avanir, Lilly, Pernix Therapeutics, and Upsher-Smith. He has received honoraria from Amgen, Inc. and Avanir.

Ward, Thomas: Dr. Thomas Ward is the Editor in Chief, Headache: The Journal of Head and Face Pain.

Weeks, Randall: Dr. Randall Weeks has nothing to disclose.

\*Planning Committee



Meeting Information:

Talley Management Group, Inc.

19 Mantua Road, Mt. Royal, NJ 08061



PH: 856-423-7222 X 263

FAX: 856-423-3420

www.hcop.com